FDA Names New Leaders for Drugs, Vaccines, Tobacco & AI Oversight

Washington – In a move that many insiders say will finally give the Food and Drug Administration a bit of breathing room, the Trump administration announced Tuesday that four senior posts have been made permanent.

First up is Dr. Michael Davis, now the director of the Center for Drug Evaluation and Research. Davis, who had been the agency’s acting chief after Dr. Tracy Beth Hoeg was let go in May, brings a mix of government and nonprofit experience – he once helped steer a psychedelic‑focused nonprofit before returning to the FDA as a deputy director last year.

That background matters because Davis will soon be staring down a wave of applications for psychedelic therapies – think psilocybin, MDMA and even LSD – that the White House is eager to see move through the approval process faster.

On the vaccine side, the agency tapped pharmacist‑executive Karim Mikhail to lead the Center for Biologics Evaluation and Research. Mikhail, a longtime pharma veteran, stepped into the acting role after Dr. Vinay Prasad resigned amid controversy over vaccine, gene‑therapy and rare‑disease drug oversight.

Prasad’s departure left a vacuum that the administration seemed keen to fill quickly; the new director is expected to keep the spotlight on COVID‑19 booster policies while also handling the ever‑growing pipeline of mRNA‑based products.

Rounding out the trio, career FDA attorney Bret Koplow was confirmed as head of the Center for Tobacco Products. Koplow has been navigating the fraught e‑cigarette and nicotine‑pouch landscape for months, and his permanent appointment should signal a steadier regulatory hand.

Finally, a brand‑new office was created to wrestle with the agency’s burgeoning technology challenges. Jared Seehafer, a longtime FDA technologist, will oversee artificial‑intelligence and other emerging‑tech initiatives, a nod to how digital tools are reshaping drug‑review processes.

Overall, the four appointments are being billed as a step toward stability after a year marked by high‑profile exits and heated debates over everything from flavored vaping products to accelerated drug pathways.